The invention is directed to a biodegradable tissue-adhesive device for sealing tissue, said device comprising a tissue-adhesive layer which comprises a blend of a tissue-reactive polymer and a biodegradable carrier polyurethane according to the formula of A-B-C-B.sub.n, wherein A denotes a polyol, B denotes a diisocyanate moiety, C denotes a diol component and n denotes the number of recurring units, and wherein the B-C-B segment is bioresorbable.

Provided herein are bio-absorbable, settable and homogenous multi-putty bone-adhesive compositions for medical use in tissue hemostasis, surgical repair and reconstruction. Also provided are improved methods of intraoperative use of said compositions for re-approximation of adjacent bone fragments to create a restored alignment and stabilize fracture line.

The present invention is directed to bioresorbable polymers to be used as bone and tissue adhesives. The present invention is also directed to the synthesis of bioresorbable polymeric molecules bearing adhesive moieties and the use of such compounds in methods to glue and stabilize fractured bones and damaged tissues. The present invention is also directed to the use of such compounds as adhesive sealants for applications in wound care. The present invention is also directed to the use of such compounds as biodegradable ink for applications in tissue engineering and 3D printing. The present invention also relates to the use of such compounds as drug delivery platforms.

Provided are compositions and methods that involve viscoelastic poly(lactide-co-caprolactone) (PLCL) mixtures for use in wound healing. The PLCL mixtures provide an improved anti-fibrotic yet tissue-adhesive polymer sealant. The PLCL mixtures can be applied to a variety of wounds arising from surgical and non-surgical tissue damage.

An ostomy device has a switchable adhesive layer located between a backing layer and an absorbent adhesive layer. The switchable adhesive layer has a photoinitiator reactive to visible light and the absorbent adhesive layer is a skin-facing layer having absorbent particles.

The present disclosure pertains to crosslinkable compositions and systems as well as methods for forming crosslinked compositions in situ, including the use of the same for embolizing vasculature including the neurovasculature within a patient, among many other uses.

Provided is a hemostatic dressing. The hemostatic dressing includes: a porous matrix layer including a biocompatible polymer; a hemostatic layer loaded on the porous matrix layer and including a polymer in which polyhydric phenol-containing moieties are introduced; and a binding layer interposed between the porous matrix layer and the hemostatic layer to prevent the porous matrix layer from being separated from the hemostatic layer.

Provided is a hemostatic dressing. The hemostatic dressing includes: a porous matrix layer including a biocompatible polymer; a hemostatic layer loaded on the porous matrix layer and including a polymer in which polyhydric phenol-containing moieties are introduced; and a binding layer interposed between the porous matrix layer and the hemostatic layer to prevent the porous matrix layer from being separated from the hemostatic layer.

A method of production of a tissue sealing patch is disclosed. The method comprises applying a vacuum to a heated work surface; applying a solution of a biocompatible polyurethane polymer to the work surface and spreading it over the work surface with a polymer blade; evaporating the solvent; heating the work surface above the softening temperature of the polymer; spreading powdered tissue sealant material over the polymer film; incorporating the tissue sealant material to a depth of 20-60 μm in the film by pressing on a release sheet placed over the powder and polymer film; removing the release sheet from the adhesive patch material; releasing the vacuum; cooling said work surface; and removing the adhesive patch material from said work surface. The biocompatible polymer preferably comprises PEG-caprolactone-lactic acid units connected by urethane linkages, the PEG having a molecular weight of 3000-3500 amu, and a CL:LA:PEG ratio of 34:2:1.

This invention relates to radiopaque polymers and to their use, particularly in the manufacture of medical devices and in methods of medical treatment, including therapeutic embolization. In particular embodiments the present disclosure relates to a hydrophilic polymer comprising pendent groups which a phenyl ring is substituted with one or more iodine groups and one or more non-iodine groups as described in more detail herein.